Top

Published in:

01-12-2020 | Antiviral Agents | Editorial

HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?

Authors: Bin Zhou, Weimeng He, Jinlin Hou

Published in: Hepatology International | Issue 6/2020

Excerpt

The hepatitis B virus (HBV) is a major human pathogen. The HBV genome encodes four overlapping open-reading frames (ORFs) including the S-ORF, C-ORF, P-ORF, and X-ORF. Among them, polymerase which encoded by P-ORF is the target of all approved nucleos(t)ide analogues (NAs) for antiviral therapy. NAs are generally efficient and well tolerated. However, resistance to non-first line antiviral agents is a major issue affecting long-term therapy [1]. HBx encoded by X-ORF is a nonstructural protein that serves multiple functions during the various stages of chronic HBV infection (CHB) through interaction with a number of host proteins. …

Lok AS, McMahon BJ, Brown RJ, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu DA, Prokop LJ, Wang Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306.CrossRef

Lin CL, Chien RN, Chu YD, Liang KH, Huang YH, Ke PY, Lin KH, Lin YH, Yeh CT. Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression. Hepatol Int. 2020. https://doi.org/10.1007/s12072-020-10079-1.CrossRefPubMedPubMedCentral

Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015;16(8):459–71.CrossRef

Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Investig. 2001;107(4):449–55.CrossRef

Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46(1):254–65.CrossRef

Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007;47(4):492–8.CrossRef

Wang T, Qin Y, Zhang J, Li X, Tong S, Zhao W, Zhang J. An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene. Virus Genes. 2020;56(6):677–86. https://doi.org/10.1007/s11262-020-01787-9.CrossRefPubMed

Zhang Y, Zhang H, Zhang J, Zhang J, Guo H. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate. Antiviral Res. 2019;165:47–54.CrossRef

Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol. 2018;30:32–8.CrossRef

Title: HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?
Authors: Bin Zhou
Weimeng He
Jinlin Hou
Publication date: 01-12-2020
Publisher: Springer India
Keywords: Antiviral Agents
Hepatitis B
Entecavir
Lamivudine
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Lamivudine
Published in: Hepatology International / Issue 6/2020
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-020-10116-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2020

Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis

COVID-19 in decompensated cirrhosis

Current perspectives on the tumor microenvironment in hepatocellular carcinoma

Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension

APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19

Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page